Sudden vision loss in one eye needs same-day care. Call an eye doctor or go to the emergency department.

Optic Nerve Health

Eye care during GLP-1 treatment

An individualized framework for optic nerve and retinal assessment

Reviewed by James Deom, OD, MPH, FAAO, Chief of Eye Care Services. Last reviewed: November 11, 2026.

Please read first. This is a proposed practice framework. It is not a validated NAION risk score or a society-mandated screening schedule. AOA recommends a baseline exam around the start of therapy, while AAO/NANOS do not recommend exams solely to predict NAION. No validated NAION-specific surveillance interval exists, and routine testing has not been shown to predict or prevent NAION.¹ ² ³ See the study comparison page for the evidence table and professional positions.

Dr. Deom’s practice approach (clinical opinion)

Dr. James Deom recommends that everyone starting or taking a GLP-1 medication have a comprehensive dilated eye exam with OCT, OCT angiography (OCTA), and retinal photography (fundus photos with autofluorescence) as a baseline and for follow-up, and seek same-day care for sudden vision loss.

This schedule is his practice recommendation, not a proven surveillance protocol. It should be individualized to exam findings, diabetic retinopathy or other established eye disease, and the medical course.

Time point His recommended approach
Baseline A comprehensive dilated exam with OCT (baseline RNFL/GCL thickness and disc structure), OCTA (baseline peripapillary, optic nerve head, and macular perfusion), and fundus photographs with autofluorescence (baseline disc appearance, crowding, possible disc drusen, and retinal disease), before starting or soon after. A practical window is within 12 months before starting or 1 month after, consistent with AOA timing.²
Follow-up Repeat the dilated exam with the same imaging set at a reasonable interval, set by the findings and the patient’s other eye-care needs. For many people this will coincide with a later comprehensive or diabetic eye exam; others may need an earlier visit. Established conditions such as diabetic retinopathy or glaucoma keep their own schedules.
Symptoms Same-day examination for any new visual symptoms, with repeat imaging as clinically indicated.

These tests document a baseline and help characterize change. They do not reliably predict or prevent an acute NAION event.

Dr. James Deom’s personal clinical thought

This is his opinion, not established evidence. It is not a finding from the studies or a position of the FDA, EMA, AAO, NANOS, or AOA.

As patients lose weight and their overall health improves on GLP-1 medicines, blood pressure and cholesterol medicines are often not re-addressed. Over-treatment of blood pressure may lead to hypotension, which can worsen at night and could cause nighttime hypoperfusion of the optic nerve. That sequence would fit the typical presentation of NAION (vision loss noticed on waking).

He recommends that people on GLP-1 medicines also improve exercise and diet, and keep regular visits with their usual doctors, even if that clinician did not prescribe the GLP-1, so the rest of their care, including blood pressure, is maintained.

For prescribers: consider reviewing antihypertensive dosing and timing (including bedtime dosing) as weight drops. Coordinate changes with the patient’s usual clinician when someone else wrote the GLP-1 prescription.

1. Identify patients who need closer assessment

  • Prior NAION in either eye, or any optic neuropathy
  • Known crowded disc, small cup-to-disc ratio, or optic disc drusen
  • Retinal vein occlusion or a hypercoagulable state
  • Multiple additional factors: age over 50, male sex, smoking, hypertension, complicated diabetes, untreated or suspected OSA, hyperlipidemia, anemia, bedtime antihypertensive use, or a history of hypotension

These categories are practical descriptions, not validated thresholds. Prior NAION or an abnormal optic nerve calls for an individualized plan.

2. Establish the baseline

Assessment Routine care When closer assessment is indicated
Visual history and acuity At eye exam At eye exam
Dilated exam and optic disc evaluation Dr. Deom: baseline for everyone starting or taking a GLP-1 RA (practical window: within 12 mo before or 1 mo after starting, consistent with AOA)² Before or soon after treatment begins; closer or earlier review if prior NAION or an abnormal disc
OCT (RNFL/GCL/disc), OCT angiography, and fundus photographs with autofluorescence Dr. Deom: include this imaging set at the baseline visit for everyone, for documentation, not prediction. All five Eye Specialists of NEPA offices (Hazleton, Stroudsburg, Nanticoke, Pottsville, Bangor) have these modalities. Repeat sooner, or add fields, when the disc or retina is abnormal or symptoms are present
Visual field If indicated Abnormal disc, symptoms, or prior NAION
Blood pressure and orthostatic symptoms Review with medical clinician Consider home readings or orthostatics if indicated
A1c, lipids, CBC Per medical care plan Review diabetes control and suspected anemia
OSA screening Review symptoms and history Refer for medical assessment when indicated
Smoking status Review and counsel Review and counsel
Antihypertensive timing Review with prescriber Coordinate changes only when clinically indicated

3. Individualize the follow-up interval

Under Dr. Deom’s practice approach, everyone has a baseline exam with OCT, OCTA, and retinal photography, then a repeat visit with the same imaging at a reasonable interval, and a same-day exam for symptoms. The points below are examples for setting that interval, not a requirement for every patient and not a validated NAION prevention schedule. Established eye disease (for example, DR or glaucoma) follows its own schedule. Risk timing in the studies is unsettled and does not end at 6 months.⁴ ⁵

Review point Typical interval (his practice approach) Closer follow-up when indicated
Dose escalation Ask about vision changes, GI losses, dizziness Coordinate BP or orthostatic assessment if indicated
About 3 months Symptom check with the medical care plan may suffice if the baseline exam was recently completed and the disc and retina were unremarkable Consider a repeat dilated exam with OCT, OCTA, and photographs based on baseline findings
About 6 months Review symptoms and new risk factors; bring the next imaging visit forward if anything has changed Repeat exam and imaging when indicated
A later comprehensive or diabetic exam (often about 12 months if findings allow) Repeat dilated exam with OCT, OCTA, and fundus photographs with autofluorescence; set the next interval according to findings Earlier return if the disc, retina, or medical course warrants it
Ongoing Continue routine and diabetic eye care, with imaging at reasonable intervals Continue individualized follow-up; reassess risk factors

4. Factors that may affect care

  • Rapid A1c reduction / diabetic retinopathy: coordinate glycemic and retinal follow-up with the prescriber. The AAO (November 2026) recommends an initial period of increased diabetic-retinopathy monitoring when a patient with diabetes starts a GLP-1 RA, especially if baseline A1c has been poorly controlled.⁶
  • Low or symptomatic blood pressure: coordinate a review of dose and timing with the prescribing clinician.
  • Dehydration from vomiting or diarrhea: address promptly, and discuss pausing escalation with the prescriber.
  • New OSA symptoms or CPAP non-adherence
  • Smoking
  • New anemia
  • New medicines that can cause hypotension or are associated with NAION (for example, PDE-5 inhibitors, amiodarone, additional antihypertensives)

5. Respond immediately to new visual symptoms

Sudden painless monocular vision loss or a new field defect needs a same-day eye assessment. Arrange ophthalmology or neuro-ophthalmology review and contact the prescriber. Evaluate for giant cell arteritis when indicated (symptoms; ESR, CRP, CBC with platelets). After NAION develops, the FDA advises considering discontinuation unless the benefits clearly outweigh the risk,¹ and AAO/NANOS advise shared decision-making.³

Document the plan

Record the relevant history, baseline disc findings, the reason for each test, the chosen follow-up interval, symptom counseling, and the shared medication decision.

Medical disclaimer. This framework is educational and intended for licensed clinicians. It is not a validated protocol or clinical practice guideline and does not replace clinical judgment, product labeling, or specialty consultation. Information is current as of the “last reviewed” date.

References

  1. U.S. FDA Drug Safety Communication, Nov 9, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
  2. AOA clinical report, June 2025. https://www.aoa.org/AOA/Documents/Practice%20Management/Clinical%20Guidelines/AOA%20GLP-1_EBO_clinical-report.pdf
  3. AAO & NANOS, Sep 22, 2026. https://www.aao.org/newsroom/news-releases/detail/what-data-say-about-glp-1-drugs-vision-loss · Consensus statement: https://www.aao.org/education/clinical-statement/glucagon-like-peptide-1-receptor-agonists-risk-of-
  4. Grauslund J, et al. Int J Retina Vitreous. 2024 (median onset 22.2 months). https://link.springer.com/article/10.1186/s40942-024-00620-x
  5. TriNetX diabetes cohort. JAMA Ophthalmol. 2025 (risk significant at 2–4 years). https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2831924
  6. American Academy of Ophthalmology. GLP-1 receptor agonists and diabetic retinopathy. November 2026. https://www.aao.org/education/clinical-statement/glucagon-like-peptide-1-receptor-agonists-diabetic